(Sharecast News) - Faron Pharmaceuticals reported a series of first-half clinical and financial milestones on Wednesday, as it advanced its lead asset, bexmarilimab, through late-stage development in high-risk myelodysplastic syndromes (HR-MDS).
The AIM-traded company confirmed plans to move into a single phase two and three registrational trial following positive phase two...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE